Better Therapeutics- Tradeable Rights - March 2021 Return on Equity

Better Therapeutics- Tradeable Rights - March 2021's return on equity stands at 317.73%. That is above the sector sector average of -5.84%. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Better Therapeutics- Tradeable Rights - March 2021 sits higher the its sector benchmark (-5.84%) with a ROE of 317.73%. That is roughly 5536.0% above the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

A ROE of 317.73% for Better Therapeutics- Tradeable Rights - March 2021 means each unit of related capital or sales is generating that return rate. Higher is usually better for profitability metrics, but extremely high figures can reflect one-time items or thin equity bases. Review several years of data on this page before extrapolating.

The history chart shows how Better Therapeutics- Tradeable Rights - March 2021's ROE evolved across reporting periods, while the comparison chart places MCADR next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.